Wide Ranks

CYCC

Cyclacel Pharmaceuticals, Inc.

0.3450

Top Statistics
Market Cap 2 M Forward PE -0.2924 Revenue Growth -98.90 %
Current Ratio 1.07 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.2570 Enterprise / Revenue -64.82 Price To Sales Trailing12 Months 27.11
Profitability
Profit Margins 0.00 % Operating Margins -91100.00 %
Balance Sheet
Total Cash 6 M Total Cash Per Share 3.04 Total Debt 5000
Total Debt To Equity 0.5010 Current Ratio 1.07 Book Value Per Share 0.5730
All Measures
Short Ratio 3.00 % Message Board Id finmb_125004 Fax 866 271 3466
Shares Short Prior Month 47934 Return On Equity -5.71 City Berkeley Heights
Uuid af38ffef-8b46-39b5-ba5d-74a2f1b0ea12 Previous Close 0.3540 First Trade Date Epoch Utc 1 B
Book Value 0.5730 Beta 0.5570 Total Debt 5000
Volume 258164 Price To Book 0.6021 Last Split Date 1 B
Fifty Two Week Low 0.3200 Total Cash Per Share 3.04 Total Revenue 80000
Shares Short Previous Month Date 1 B Target Median Price 1.00 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -91100.00 % Target Mean Price 1.00
Net Income To Common -17606000 Short Percent Of Float 0.0323 Implied Shares Outstanding 6 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 374790
Average Volume10days 374790 Total Cash 6 M Next Fiscal Year End 1 B
Revenue Per Share 0.0440 Held Percent Insiders 0.0482 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.3540
Target Low Price 1.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.7356
Open 0.3480 Free Cashflow -7656750 State NJ
Dividend Yield 0.00 % Return On Assets -1.03 Time Zone Short Name EST
Trailing Eps -27.40 Day Low 0.3350 Address1 200 Connell Drive
Shares Outstanding 6 M Price Hint 4 Target High Price 1.00
Website https://www.cyclacel.com 52 Week Change -0.9222 Average Volume 1 M
Forward Eps -1.99 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 97.00 % Last Split Factor 1:15 Regular Market Day High 0.3550
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 0.5010
Fifty Two Week High 6.00 Day High 0.3550 Shares Short 66765
Regular Market Open 0.3480 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue -64.82 Revenue Growth -98.90 % Shares Percent Shares Out 0.0310
Operating Cashflow -11513000 Currency USD Time Zone Full Name America/New_York
Market Cap 2 M Is_nasdaq_100 False Zip 07922
Quote Type EQUITY Industry Biotechnology Long Name Cyclacel Pharmaceuticals, Inc.
Regular Market Day Low 0.3350 Held Percent Institutions 0.1803 Current Price 0.3450
Address2 Suite 1500 Enterprise To Ebitda 0.2570 Financial Currency USD
Current Ratio 1.07 Gross Margins 100.00 % Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country United States Float Shares 1 M
Two Hundred Day Average 1.59 Enterprise Value -5185576 Price To Sales Trailing12 Months 27.11
Forward PE -0.2924 Regular Market Volume 258164 Ebitda -20185000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.

The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.

It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.

The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.